Donald Trump: What medtech’s top executives are saying

“ACA, repeal and replacement, we’re paying a lot of attention to that. The obvious benefit that is out there is a full repeal of the medical device tax. We’re in the second year of the suspension at this point in time. We get the question oftentimes … as to whether or not we would expect some kind of a volume decline to the extent that the ACA was repealed and not fully replaced, and that’s in excess to care question obviously. And all along, our measurements would indicate that volume might have been positively impacted by tens of basis points. And so, we don’t see that as being a significant risk to our volumes going forward. And another question that we get often times is [Medicare’s Comprehensive Care for Joint Replacement model] and what happens in that regard with any potential reforms or repeals of the ACA. We think that those end-to-end episode of care reimbursement models, whether it’s in a public or a private setting, our innovation and the go-to market strategy that is probably here to stay in some form, one can speculate as to what the specific form might be as it relates to Medicare in the United States. But, our Signature Solutions offering is geared towards enhancing patient outcomes and driving efficiencies and in the implementation or delivery of that care across the entire episode of care.” —Zimmer Biomet CEO David Dvorak, Jan. 31

Next>>